Key Points {#d29e462}
==========

A range of factors affect pathogenesis, presentation, and prognosis of osteoarthritis.These factors could have an impact on response to symptomatic or structural treatments for osteoarthritis.There is some evidence that patients with early disease respond better to pharmacological treatments for osteoarthritis than those with late disease.Treatment decisions should be made considering clinical presentation, underlying pathophysiology, and the stage of disease.

Introduction {#Sec1}
============

Osteoarthritis is progressive chronic disease potentially affecting every articular tissue, and may potentially lead to joint failure. It has heterogeneous manifestations, and does not always have the same appearance in all patients. Indeed, osteoarthritis may present differently in men and women \[[@CR1], [@CR2]\], in patients with or without trauma, in athletes, or in obese patients. This raises the possibility that osteoarthritis patients with different profiles could require different treatments.

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) has already explored a variety of pivotal issues in osteoarthritis, including the question of how best to define responders to treatment for drug development \[[@CR3]\], and the value of biomarkers and magnetic resonance imaging (MRI) in the diagnosis of the disease and the prediction of the hard outcome of joint replacement surgery \[[@CR4], [@CR5]\]. In a new meeting in October 2013, an ESCEO--EUGMS (European Union Geriatric Medicine Society) working group discussed the possibility of identifying patients who would benefit most from treatment for osteoarthritis. The hypothesis discussed was that there may be different patient profiles according to mechanical or systemic features of the disease, or stage of the disease. This may have a variable impact on how patients react to treatments, and possibly even provide an explanation for the failure of clinical trials in osteoarthritis. Indeed, personalized medicine may prove to be advantageous in osteoarthritis insofar as it is a heterogeneous disease, with variable progression, and there is no standardized treatment that works in all patients \[[@CR6]\]. The ultimate aim of these discussions is to lead to a more personalized clinical approach and cost-effective care for patients with osteoarthritis. This article is a summary of these discussions.

Process and Outcomes {#Sec2}
====================

We identified relevant articles, reviews, and abstracts in a search of PubMed/MEDLINE and EMBASE for English-language articles published between 1990 and October 2013. The initial search strategy included the terms osteoarthritis, risk factor, predictor, progression, guidelines, biomarkers, MRI, and phenotype, and yielded 463 items. Separate subsearches were also performed using a cross-search of the above terms combined, and additional references were selected from the reference lists of selected articles and the presentations made during the working meeting. The narrative is therefore largely based upon expert opinion. Overall, 73 relevant items were selected by the authors according to their quality and pertinence for discussion by the ESCEO working group.

Epidemiology and Risk Factors for Progression {#Sec3}
---------------------------------------------

The general definition of osteoarthritis is a group of overlapping disorders with similar structural and clinical outcomes \[[@CR7]\]. Indeed, osteoarthritis can affect articular cartilage, subchondral bone, synovium, meniscus, muscle, capsule, and ligaments. This definition of osteoarthritis may be important for the characterization of patient profiles, since it determines what sort of information is to be captured, i.e., structural, clinical, or surgical. Osteoarthritis has been classified into three subsets according to distinct etiological, clinical, and therapeutic characteristics: estrogen deficiency-related, genetically-induced, and age-related (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1], [@CR2]\]. This proposal is based on the etiology and pathogenesis of osteoarthritis \[[@CR2]\], and combines the three main biological processes crucial for the development of osteoarthritis, together with additional risk factors such as obesity, the metabolic syndrome, and trauma. Understanding the pathogenesis of the disease is important for determining patient profiles in order to establish rational treatment in osteoarthritis. Another important consideration is that osteoarthritis is usually an insidiously progressive disease, and a patient's profile may evolve over the course of the disease \[[@CR8]\]. It has been proposed that all of the clinical forms are interchangeable in the early stages of disease and may appear as differing clinical profiles in various tissues \[[@CR9]\]. In more advanced disease, clinical and imaging presentations become more generalized and profiles may overlap.Fig. 1Three subsets of osteoarthritis with distinct etiological, clinical, and therapeutic characteristics. Adapted from Herrero-Beaumont et al. \[[@CR2]\], with permission

In the research setting, osteoarthritis is generally classified radiographically, most typically using the Kellgren--Lawrence (KL) grading system \[[@CR10], [@CR11]\]. Although the correlation is not always linear \[[@CR12], [@CR13]\], the osteoarthritis patients with the most pain tend to have the highest KL grades.

Osteoarthritis has a high incidence. A recent study in a Spanish population including more than 3 million individuals reported incidence rates of clinically diagnosed osteoarthritis of 6.5, 2.1, and 2.4 per 1,000 person-years for knee, hip, and hand, respectively \[[@CR14]\]. The incidence of osteoarthritis increases with age, rising sharply beyond the age of 50 years and leveling off after the age of 80 years \[[@CR7], [@CR14]--[@CR16]\]. It is considerably more common in women than in men \[[@CR7], [@CR15], [@CR16]\]. For example, in the Spanish study, the incidence rate of knee osteoarthritis in women was 8.3 per 1,000 person-years versus 4.6 per 1,000 person-years for men \[[@CR14]\]. In view of the high prevalence and high cost of the surgical consequences of joint failure, osteoarthritis constitutes a major healthcare burden. The situation may even be worsening, since the rates of total hip replacement have increased and there are signs that joint replacement may be occurring at an earlier age \[[@CR17]\]. The notion of healthcare burden is also important since patients with osteoarthritis are at higher risk for mortality than the general population, and there have been calls for a more unified approach to healthcare in these patients, including effective management of cardiovascular risk factors and co-morbidities \[[@CR18], [@CR19]\].

There are many risk factors for osteoarthritis, including systemic factors, such as age, sex, body mass index (and obesity), genetic factors, bone density, and estrogen status, and local biomechanical factors, such as obesity, physical activity or occupation, intense sporting activity, joint injury or deformity, and muscle weakness \[[@CR7]\]. Some of these are also risk factors for progression of the disease. The three risk factors that appear to most consistently predict progression are obesity, generalized osteoarthritis, and synovitis/effusion \[[@CR20]\]. Joint space narrowing over 5 years has recently been demonstrated to predict future knee replacements up to 15 years later \[[@CR21], [@CR22]\]. There are many epidemiological studies on progression of osteoarthritis. In one analysis performed in the Chingford Women's Study \[[@CR23]\], the progression of radiographic knee osteoarthritis, i.e., KL grade, was recorded in a sample of 561 patients. Although more than half of patients had no progression with stable KL grades over 15 years, patients with KL grade 1 were twice as likely to progress as those with KL grade 0 \[[@CR24]\]. While the evidence points to a rapid progression of patients with early disease, it should be treated with caution due to the possibility of collider bias, which is a potential confounder in any analysis involving selection of patients at baseline on the basis of a characteristic that is also a risk factor.

Current treatment guidelines in osteoarthritis generally agree that it requires a combination of non-pharmacological and pharmacological modalities \[[@CR25]--[@CR31]\]. Management should start with non-pharmacological therapy, and if symptoms persist a stepwise increase in treatment intensity should follow, starting with over-the-counter treatments, then prescription treatments for pain control, and then, if needed, referral for surgery; opioid analgesics are generally reserved for patients who cannot receive surgery. Regulatory guidelines are also available for drug development in the symptomatic and structural management of osteoarthritis \[[@CR32]\]. None of these guidance documents provide any information on which patients should be treated.

Identification of Patient Profiles in Osteoarthritis {#Sec4}
----------------------------------------------------

The characterization of patient profiles appears as an important priority for osteoarthritis for a number of reasons. First, it would help to better orientate research and understand the disease, which would in turn improve its management. Second, it would facilitate the design of randomized clinical trials in the field and the development of new pharmacological strategies. Third, it would help to better determine which patients are the most likely to benefit from which treatment, leading to more personalized medicine and more effective use of healthcare \[[@CR6]\].

Osteoarthritis is a heterogeneous disorder and the various patient profiles will be influenced by many different factors (Table [1](#Tab1){ref-type="table"}), all of which may impact response to treatment and some of which are interdependent. These include factors related to morphology and anatomy, the type of tissue that is affected, the presence of co-morbidities, and the clinical presentation.Table 1Possible factors influencing patient profile in osteoarthritis, which might also affect response to treatmentMorphology and anatomy (biomechanical aspects) Local vs. generalized disease Monoarticular vs. polyarticular disease Alignment (or lack thereof) Ligamentous laxity Trauma Location (hand/knee vs. hip) Femoropatellar joint vs. tibiopatellar jointTissue affected Bone vs. cartilage vs. synovium Subchondral bone osteopenia vs. subchondral bone sclerosisCo-morbidities Obesity Metabolic syndrome OsteoporosisClinical presentation Symptoms (pain) vs. structure Early- vs. late-stage disease Inflammation Age Male vs. female

The identification of patient profiles will necessarily involve the use of biomarkers and imaging markers, as has been discussed previously by the ESCEO \[[@CR4], [@CR5]\]. Although there are a number of promising candidates for biomarkers \[[@CR5], [@CR33], [@CR34]\], such as urinary C-terminal telopeptide of collagen type II (CTX-II) and serum cartilage oligomeric protein (COMP), none is sufficiently discriminating for diagnosis or prediction of prognosis in patients or for use as a surrogate outcome in clinical trials. As regards imaging, radiographic joint space width or narrowing remain the recommended parameters according to the regulatory bodies \[[@CR35]\]. On the other hand, MRI markers also provide a good measure of cartilage morphometry \[[@CR4], [@CR36]\], meniscal damage \[[@CR37]\], bone marrow lesion \[[@CR37]\], and synovial effusion \[[@CR38], [@CR39]\].

### Profiles According to Articular Involvement: Local or Generalized Inflammation-Driven Osteoarthritis {#Sec5}

Generalized osteoarthritis may be a different profile from local osteoarthritis. The term 'generalized osteoarthritis' is widely used in the literature with a variety of conflicting definitions \[[@CR40]\]. In the context of our discussion, we consider generalized osteoarthritis as representing a systemic disease affecting a number of different joints at the same time, i.e., it is polyarticular. This is a feature of osteoarthritis co-morbid with inflammation or the metabolic syndrome. On the other hand, local osteoarthritis occurs in a single joint, i.e., it is monoarticular, and is typical of post-traumatic osteoarthritis. It could be surmised that biological markers would be more suitable for identification of the profile of generalized osteoarthritis, while imaging markers would be more effective for exploration of local effects post-trauma. Similarly, within the range of biomarkers, serum measurements may provide a better measure of generalized osteoarthritis (cartilage and bone sources), while intra-articular biomarkers may better characterize local osteoarthritis \[[@CR41], [@CR42]\]. Ongoing genetic studies in more than 2,500 patients with generalized osteoarthritis are set to detect linkage of circulating biomarkers to osteoarthritis-associated genes, and may shed further light on the possibilities of genetic profiling for the disease \[[@CR43]\]. There is contradictory evidence surrounding the role of inflammation, with reports that serum high-sensitivity C-reactive protein may or may not be associated with structural progression and symptoms \[[@CR44]--[@CR48]\]. An alternative explanation is that this is related to a high body mass index or the presence of the metabolic syndrome.

### Early Versus Late: Profiles According to Structural Damage and Response to Treatment {#Sec6}

Patients in the early stages of osteoarthritis, i.e., those with less severe disease, may have a separate profile from patients with advanced osteoarthritis, i.e., those with very severe disease. This is an important point since there is evidence that response to treatment may depend on a number of factors related to severity, e.g., extent of structural damage or the site of osteoarthritis (hand, knee, or hip). A dedicated PubMed search using "predictor" as a MeSH term yielded 13 studies on predictors of response in knee osteoarthritis (Table [2](#Tab2){ref-type="table"}) (including five studies in a single systematic review on steroid injection) \[[@CR49]--[@CR57]\]. All of the studies involved assessment of structure via radiography, usually with some evaluation of symptoms. They cover a wide variety of potential treatments including doxycycline, weight loss, cindunistat, corticosteroid injection, chondroitin sulphate, glucosamine, and celecoxib. The overall conclusion from the studies is that patients with the least severe knee osteoarthritis (i.e., those with the largest joint space width early disease or with a low KL grade) are more likely to benefit from effective treatment than those with more severe disease (a smaller joint space width or higher KL grade). This implies that the most powerful predictor of treatment response is severity of osteoarthritis, with the least symptomatic patients, i.e., those with early stage disease, likely to have the best response to treatment. Patients with more advanced osteoarthritis, with extensive structural damage to the joint or malalignment, appear less likely to respond.Table 2Studies in knee osteoarthritis assessing predictors of response to treatmentReferencesTreatment being testedPatients; durationMain evaluationConclusionMazzuca et al. \[[@CR49]\]Doxycycline379 patients; 16 monthsRadiographyPatients with neutral joint structure at baseline respond better to treatment than those with varus malalignmentGudbergsen et al. \[[@CR50]\]Weight loss30 patients; 32 weeksMRI/radiographyBaseline joint structure did not correlate with symptomatic progressionGudbergsen et al. \[[@CR51]\]Weight loss175 patients; 16 weeksMRI/radiographyRadiographic grade did not predict response to symptomatic reliefHellio le Graverand et al. \[[@CR52]\]Cindunistat1,457 patients; 2 yearsRadiographyPatients with less severe OA (KL grade 2) at baseline were more responsive to treatment than those with more severe disease (KL grade 3)Maricar et al. \[[@CR53]\]CorticosteroidsSystematic review (5 studies)RadiographyRadiographic severity was a predictor (2 studies): the more severe the OA, the less likely the patient was to have symptomatic response\
Radiographic OA grading did not predict response (2 studies)\
Arthroscopic cartilage grading was not linked to response (1 study)Sawitzke et al. \[[@CR54]\]Chondroitin sulphate, glucosamine, and celecoxib572 patients; 2 yearsRadiographyPatients with mild OA (KL grade 2) at baseline responded better to treatment than patients with higher KL gradeBennett et al. \[[@CR55]\]Glucosamine sulphate39 patients; 12 weeksRadiographyPatients with less severe OA at baseline had a better symptomatic response to treatmentBruyère et al. \[[@CR56], [@CR57]\]Glucosamine sulphate212 patients; 3 yearsRadiographyPatients with less severe OA at baseline had the most dramatic progression of disease*KL* Kellgren--Lawrence, *MRI* magnetic resonance imaging, *OA* osteoarthritis

There are a number of methodological issues with the studies included in Table [2](#Tab2){ref-type="table"} (e.g., heterogeneity of the data, small studies, low statistical power, placebo effects, regression to the mean, confounding factors, ceiling effects with the use of radiography, and collider bias). These observations therefore require careful interpretation and further research to ascertain the validity of any conclusion.

### Profiles According to the Biomechanical Properties of the Joint {#Sec7}

There is an increasing weight of evidence that biomechanical aspects may affect the incidence and progression of osteoarthritis \[[@CR58], [@CR59]\]. One example of this comes from an MRI study, which indicated that the presence of cam deformity femoroacetabular impingement appeared to predict the onset of hip osteoarthritis \[[@CR60]\]. The most important contributors to progression appear to be joint malalignment, loss of meniscal function, and ligament injury, and so it is likely that the same biomechanical aspects could also determine response to treatment. Other mechanical factors such as joint injury, obesity, and sport may also play a role \[[@CR61], [@CR62]\]. This raises the possibility of different profiles according to joint morphology and biomechanical function.

Biomechanical factors should be taken into account in the management of osteoarthritis. For example, correction of malalignment using a wedge insole has been reported to be highly effective in relieving pain and function in valgus knee osteoarthritis \[[@CR63]\]. Similarly, use of a medial collagen meniscus implant in patients with meniscus injuries was shown to improve pain, activity, and radiological outcomes over 10 years compared with patients with partial medial meniscectomy \[[@CR64]\]. There is also evidence that deformity or malalignment could have an effect on the efficacy of treatments for osteoarthritis. In one of the studies in Table [2](#Tab2){ref-type="table"}, patients with neutral joint structure at baseline responded better to the structural effects of treatment with doxycycline than those with varus malalignment \[[@CR49]\].

### Profiles According to the Role of the Subchondral Bone {#Sec8}

There is evidence that there are two separate patient profiles related to lesions in the subchondral bone. Although alterations in the subchondral bone appear to play a crucial role in the development and progression of osteoarthritis \[[@CR65]\], the literature on the relationship between osteoarthritis and osteoporosis remains mixed on the subject \[[@CR66]--[@CR68]\]. We should recall that despite increase bone volume fraction, subchondral bone is hypomineralized and of inferior quality in osteoarthritis. One hypothesis is that the subchondral bone remodeling observed in osteoarthritis is different from that in osteoporosis \[[@CR69], [@CR70]\]: increased bone mineral density (i.e., increased bone formation) is associated with subchondral bone sclerosis, while decreased bone mineral density (i.e., increased resorption) is associated with subchondral bone osteopenia. Animal experiments indicate that osteoporosis aggravates the progression and severity of osteoarthritis \[[@CR71], [@CR72]\], possibly due to subchondral bone fragility \[[@CR73], [@CR74]\].

The presence of two patient profiles may have direct implications for the effect of bone-active treatments in osteoarthritis. Indeed, response to treatment may vary according to whether the subchondral bone lesion has a sclerosis phenotype or an osteoporotic phenotype \[[@CR75], [@CR76]\], and patients with the osteoporotic profile could gain more benefit from bone-active treatments \[[@CR69], [@CR77]--[@CR79]\]. More research into this is necessary, especially since varying results have been found with antiresorptive agents in osteoarthritis \[[@CR80], [@CR81]\]. On the other hand, subchondral bone mineral density should be assessed in osteoporosis patients with other risk factors for osteoarthritis in order to establish an early treatment \[[@CR76]\].

Discussion {#Sec9}
==========

Osteoarthritis is a complex disease with varying influences on its natural history. There is currently a strong promise of therapeutic intervention. A range of factors affect its pathogenesis, presentation, and prognosis: joint morphology and anatomy, the specific type of tissue affected, the presence of co-morbidities, and the clinical presentation (Table [2](#Tab2){ref-type="table"}). All of these factors could have an impact on response to symptomatic or structural treatments for osteoarthritis, leading to the possibility that different patient profiles have differing responses. Further research is necessary in the field before this can be applied in clinical practice.

We have explored the various possible patient profiles in osteoarthritis. The most logical pair of profiles is generalized osteoarthritis (i.e., polyarticular or systemic disease, which may be linked to inflammatory disorders or the metabolic syndrome) and local osteoarthritis (i.e., monoarticular, which is more likely in post-trauma patients or in cases of malalignment). While this separation is clear in clinical practice, i.e., the post-trauma patient presents very differently from the metabolic syndrome patient, whether they respond in the same manner to pharmacological treatments for osteoarthritis remains an issue for the research agenda.

By contrast, there is some evidence that patients with early disease respond better to pharmacological treatments for osteoarthritis than those with late disease. Further research is essential to validate these findings in light of a variety of methodological issues such as statistical power and collider bias. Another confounder may be the observation that patients with the most pain are more likely to receive treatment. Interestingly, patients with obesity have higher levels of pain for the same level of structural damage \[[@CR82]\], which suggests that they too may respond differently to treatment. The separation into early and late profiles does have some weight, insofar as late-stage disease, in which joint morphology is the most affected, is best managed with surgical intervention rather than pharmacologically.

Further research into the role of the subchondral bone is likely to confirm the separation of patient profiles according to subchondral bone osteopenia or sclerosis. This is important in the light of a possible impact on response to bone-active treatments in osteoarthritis.

Treatment decisions should be made considering clinical presentation, underlying pathophysiology (function or structure, the presence of inflammation, the metabolic syndrome, adiposity, X-ray damage, functional impairment, and co-morbidities), and the stage of disease (early vs. late). In a future paper, the ESCEO group will explore how the various therapeutic options can be expected to act on the patient profiles in Table [2](#Tab2){ref-type="table"}. This in turn will lead to more personalized healthcare, with targeted treatment for osteoarthritis.
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